公开(公告)号：US08282917B2

公开(公告)日：2012-10-09

申请号：US12750410

申请日：2010-03-30

申请人： John C. Bell ,  Brian D. Lichty ,  David F. Stodjl

发明人： John C. Bell ,  Brian D. Lichty ,  David F. Stodjl

IPC分类号： A61K35/76

CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K39/205 ,  A61K2039/522 ,  A61K2039/5254 ,  A61K2039/572 ,  A61K2039/585 ,  C07K14/005 ,  C07K2319/07 ,  C12N2760/20222 ,  C12N2760/20232 ,  C12N2760/20234 ,  C12N2760/20261

摘要： The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.

摘要翻译： 本发明提供了在体内减毒的受感染细胞中阻断mRNA或蛋白质的核转运能力降低的突变病毒。 本发明的突变病毒还可能能够触发正常宿主细胞的抗病毒系统，同时对这些系统的作用保持敏感。 本发明还提供了在一系列应用中使用突变病毒，包括但不限于作为治疗癌症和感染的治疗剂，作为疫苗和佐剂，作为病毒载体，以及作为溶瘤和细胞溶解剂 选择性裂解恶性或感染细胞。

公开(公告)号：US20110206640A1

公开(公告)日：2011-08-25

申请号：US13060028

申请日：2009-08-20

申请人： John C. Bell ,  Fabrice Le Boeuf

发明人： John C. Bell ,  Fabrice Le Boeuf

IPC分类号： A61K35/76 ,  A61P35/00

CPC分类号： A61K38/162 ,  A61K35/76 ,  A61K35/766 ,  A61K38/193 ,  C12N2710/24132 ,  C12N2760/20232 ,  A61K2300/00

摘要： In one aspect, the invention provides methods for preferentially killing target proliferating cells in a host, such as cancer cells, by infecting host tissues with two or more strains of virus. The strains of virus may be selected to provide a synergistic and symbiotic effect, involving a contemporaneous lytic infection in the target proliferating cells. In selected embodiments, the viruses are selected so that expression of a first virulence factor in proliferating cells infected with the first virus increases the lytic effect of the second virus; and, expression of the second virulence factor in proliferating cells infected with the second virus increases the lytic effect of the first virus. The genomes of the first and second viruses may be selected so that they are incompatible for recombination between the viral genomes in cells of the host.

摘要翻译： 一方面，本发明提供了通过用两种或多种病毒株感染宿主组织来优先杀死宿主例如癌细胞中的靶增殖细胞的方法。 可以选择病毒株以提供协同和共生作用，其涉及目标增殖细胞中的同时溶解感染。 在选择的实施方案中，选择病毒使得第一毒力因子在被第一病毒感染的增殖细胞中的表达增加了第二病毒的溶解作用; 并且第二种毒力因子在用第二种病毒感染的增殖细胞中的表达增加了第一种病毒的溶解作用。 可以选择第一和第二病毒的基因组，使得它们与宿主细胞中的病毒基因组之间的重组不相容。

公开(公告)号：US20120275999A1

公开(公告)日：2012-11-01

申请号：US13514837

申请日：2010-12-10

申请人： John C. Bell ,  David F. Stojdl

发明人： John C. Bell ,  David F. Stojdl

IPC分类号： A61K35/76 ,  A61K51/00 ,  A61P35/00 ,  C12N7/04 ,  C12N5/09

CPC分类号： C12N7/00 ,  A61K35/766 ,  A61K35/768 ,  A61K45/06 ,  C12N2760/20021 ,  C12N2760/20032 ,  C12N2760/20062 ,  C12N2760/20071 ,  A61K2300/00

摘要： Embodiments of the invention include compositions and methods related to Maraba virus and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.

摘要翻译： 本发明的实施方案包括与Maraba病毒相关的组合物和方法及其作为抗癌治疗剂的用途。 这样的弹状病毒在体外和体内具有肿瘤细胞杀伤性质。

公开(公告)号：US20100272687A1

公开(公告)日：2010-10-28

申请号：US12750410

申请日：2010-03-30

申请人： John C. Bell ,  Brian D. Lichty ,  David F. Stojdl

发明人： John C. Bell ,  Brian D. Lichty ,  David F. Stojdl

IPC分类号： A61K35/76 ,  A61P35/00

CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K39/205 ,  A61K2039/522 ,  A61K2039/5254 ,  A61K2039/572 ,  A61K2039/585 ,  C07K14/005 ,  C07K2319/07 ,  C12N2760/20222 ,  C12N2760/20232 ,  C12N2760/20234 ,  C12N2760/20261

摘要： The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.

摘要翻译： 本发明提供了在体内减毒的受感染细胞中阻断mRNA或蛋白质的核转运能力降低的突变病毒。 本发明的突变病毒还可能能够触发正常宿主细胞的抗病毒系统，同时对这些系统的作用保持敏感。 本发明还提供了在一系列应用中使用突变病毒，包括但不限于作为治疗癌症和感染的治疗剂，作为疫苗和佐剂，作为病毒载体，以及作为溶瘤和细胞溶解剂 选择性裂解恶性或感染细胞。

公开(公告)号：US20090317362A1

公开(公告)日：2009-12-24

申请号：US12549939

申请日：2009-08-28

申请人： Grant McFadden ,  John C. Bell

发明人： Grant McFadden ,  John C. Bell

IPC分类号： A61K35/76 ,  A61P31/12

CPC分类号： A61K35/768 ,  C12N2710/24032

摘要： The present invention relates to therapeutic use of Myxoma virus. Myxomas virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer.

摘要翻译： 本发明涉及粘液瘤病毒的治疗用途。 粘液瘤病毒可以选择性感染具有缺陷先天性抗病毒反应的细胞，包括对干扰素无反应的细胞，可用于治疗特征在于存在这种细胞（包括癌症）的疾病。

公开(公告)号：US07582614B2

公开(公告)日：2009-09-01

申请号：US10547859

申请日：2004-03-08

申请人： Grant McFadden ,  John C. Bell

发明人： Grant McFadden ,  John C. Bell

IPC分类号： A61K31/70 ,  C12N7/00

CPC分类号： A61K35/768 ,  C12N2710/24032

摘要： The present invention relates to therapeutic use of Myxoma virus. Myxoma virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer.

摘要翻译： 本发明涉及粘液瘤病毒的治疗用途。 粘液瘤病毒可以选择性感染具有缺陷先天性抗病毒反应的细胞，包括对干扰素无反应的细胞，并可用于治疗特征在于存在这种细胞（包括癌症）的疾病。

公开(公告)号：US06940421B2

公开(公告)日：2005-09-06

申请号：US09730170

申请日：2000-12-05

申请人： Roger D. Chamberlain ,  John C. Bell

发明人： Roger D. Chamberlain ,  John C. Bell

IPC分类号： H04L12/26 ,  G08C15/00

CPC分类号： H04L43/06

摘要： A remote telemetry system utilizing dual communication pathways comprising low-cost remote communications devices operating on existing wire-based communications systems, wireless communications systems, and/or a combination thereof, to provide real-time reading and control of the remote telemetry units. A central controller directs the operation of the remote telemetry units and receives data from the remote telemetry units. The central controller is configured to utilize a conventional broadcast communications channel to transmit commands to individual remote telemetry units, each of which is assigned a unique identification code. Signals broadcast from the central controller are received at receivers associated with each remote telemetry unit, which performs a directed operation if a unique identification code included in the broadcast signal matches the identification code assigned to the remote telemetry unit. Each remote telemetry unit is provided with access to a conventional shared two-way communication pathway for return communication to the central controller. The shared two-way communication pathway is inactive unless specifically activated by a remote telemetry unit upon receipt of a signal from the central controller. In this manner, a large number of remote telemetry units may be provided with regulated access to a single shared two-way communications channel.

摘要翻译： 一种使用双通信路径的远程遥测系统，包括在现有有线通信系统，无线通信系统和/或其组合上操作的低成本远程通信设备，以提供远程遥测单元的实时读取和控制。 中央控制器引导远程遥测单元的操作并从远程遥测单元接收数据。 中央控制器被配置为利用常规广播通信信道将命令发送到各个远程遥测单元，每个远程遥测单元被分配唯一的识别码。 在与每个远程遥测单元相关联的接收机处接收从中央控制器广播的信号，如果包括在广播信号中的唯一识别码与分配给远程遥测单元的识别码匹配，则执行定向操作。 每个远程遥测单元都具有访问常规的共享双向通信路径，用于返回到中央控制器的通信。 共享双向通信路径是无效的，除非在远程遥测单元接收到来自中央控制器的信号时特别激活。 以这种方式，可以向大量的远程遥测单元提供对单个共享双向通信信道的受控访问。

公开(公告)号：US4766547A

公开(公告)日：1988-08-23

申请号：US851787

申请日：1986-04-14

申请人： Richard G. Modery ,  John C. Bell ,  Charles R. Cope

发明人： Richard G. Modery ,  John C. Bell ,  Charles R. Cope

IPC分类号： B65G43/00 ,  B61L23/00 ,  B61L27/04 ,  B65G37/00 ,  G06F15/46

CPC分类号： B61L23/005 ,  B61L27/04

摘要： A computer-controlled overhead conveyor system is provided wherein all conveyor vehicles substantially continually communicate with a control system to be routed through the track network. The track is conceptually divided into zones each identified by an optically read marker; and the vehicles include scanners for reading the markers as the vehicles traverse the track. The marker information is communicated to the control system which controls track switches and vehicle velocities to prevent collisions and to direct the vehicles to desired destinations. Preferably, each vehicle includes a circuit for indicating the weight of the load transported thereby; and the control system calculates running totals of material weight moved--for example by material type or by track station. Further preferably, the control system controls the acceleration/deceleration of each vehicle in a manner dependent on the material type and weight to effect the maximum vehicle speeds while preventing damage to vehicle loads.

摘要翻译： 提供了一种计算机控制的架空输送机系统，其中所有输送机车辆基本上连续地与要通过轨道网络路由的控制系统进行通信。 轨道在概念上被划分为由光学读取标记识别的区域; 并且车辆包括当车辆穿过轨道时读取标记的扫描器。 标记信息被传送到控制轨道开关和车辆速度的控制系统，以防止碰撞并将车辆引导到期望的目的地。 优选地，每个车辆包括用于指示由此传送的负载的重量的电路; 并且控制系统计算移动的材料重量的运行总计，例如通过材料类型或轨道站。 进一步优选地，控制系统以取决于材料类型和重量的方式控制每个车辆的加速/减速，以实现最大车速，同时防止对车辆负载的损坏。

公开(公告)号：US08227440B2

公开(公告)日：2012-07-24

申请号：US12549939

申请日：2009-08-28

申请人： Grant McFadden ,  John C. Bell

发明人： Grant McFadden ,  John C. Bell

IPC分类号： A61K48/00 ,  A01N65/00

CPC分类号： A61K35/768 ,  C12N2710/24032

摘要： The present invention relates to therapeutic use of Myxoma virus. Myxomas virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer.

摘要翻译： 本发明涉及粘液瘤病毒的治疗用途。 粘液瘤病毒可以选择性感染具有缺陷先天性抗病毒反应的细胞，包括对干扰素无反应的细胞，可用于治疗特征在于存在这种细胞（包括癌症）的疾病。

公开(公告)号：US20100086522A1

公开(公告)日：2010-04-08

申请号：US12374277

申请日：2007-07-18

申请人： John C. Bell ,  Anthony T. Power

发明人： John C. Bell ,  Anthony T. Power

IPC分类号： A61K35/76 ,  C12N5/00

CPC分类号： A61K35/766 ,  A61K47/6901 ,  A61K2039/515 ,  C12N2760/20232

摘要： The invention provides compositions and methods for treating neoplastic disease, such as cancer, with an oncolytic virus, such as VSV. A carrier cell is used to target a diseased tissue, and to cloak the oncolytic virus from surveillance by the subject's immune system during a targeting interval. Following delivery of the virus to the target tissue, the lysis of the carrier cell, and of the target cell, by the oncolytic virus, promotes an adaptive tumouricidal immune response. A wide variety of disparate carrier cells may be used, in conjunction with a promiscuous oncolytic virus having broad tropism, in an approach which facilitates successive treatments in which a new carrier will not be susceptible to an adaptive immune response mounted against previously used carriers. The promiscuity of the virus also facilitates lysis of carrier cells and target cells that are allogenic or xenogenic. The lytic phase of the carrier cell infection is staged so that the carrier is administered in an eclipse phase, and lysis follows the conclusion of the therapeutic targeting interval.

摘要翻译： 本发明提供了用溶瘤病毒如VSV治疗肿瘤疾病如癌症的组合物和方法。 载体细胞用于靶向患病组织，并且在靶向间隔期间通过受试者的免疫系统对溶瘤病毒进行遮盖。 在将病毒递送至靶组织后，溶瘤病毒对载体细胞和靶细胞的裂解促进适应性的免疫反应。 可以使用多种不同的载体细胞，与具有广泛趋向性的混杂溶瘤病毒联合使用，其有利于连续治疗，其中新载体不会对针对先前使用的载体安装的适应性免疫应答敏感。 病毒的混杂也有助于溶解同种异体或异种的载体细胞和靶细胞。 载体细胞感染的裂解期分期进行，使得载体在日食阶段施用，并且裂解遵循治疗靶向间隔的结论。